Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
28
Employees28
Headquarters
Calgary, Alberta
HeadquartersCalgary, Alberta
Founded
1998
Founded1998
Employees
28
Employees28

ONCY Key Statistics

Market cap
104.31M
Market cap104.31M
Price-Earnings ratio
-3.44
Price-Earnings ratio-3.44
Dividend yield
Dividend yield
Average volume
541.12K
Average volume541.12K
High today
$1.01
High today$1.01
Low today
$0.9601
Low today$0.9601
Open price
$0.997
Open price$0.997
Volume
693.27K
Volume693.27K
52 Week high
$1.51
52 Week high$1.51
52 Week low
$0.3258
52 Week low$0.3258

Stock Snapshot

The current Oncolytics Biotech(ONCY) stock price is $0.97, with a market capitalization of 104.31M. The stock trades at a price-to-earnings (P/E) ratio of -3.44.

On 2026-01-10, Oncolytics Biotech(ONCY) stock traded between a low of $0.96 and a high of $1.01. Shares are currently priced at $0.97, which is +0.6% above the low and -4.4% below the high.

Oncolytics Biotech(ONCY) shares are trading with a volume of 693.27K, against a daily average of 541.12K.

In the last year, Oncolytics Biotech(ONCY) shares hit a 52-week high of $1.51 and a 52-week low of $0.33.

In the last year, Oncolytics Biotech(ONCY) shares hit a 52-week high of $1.51 and a 52-week low of $0.33.

ONCY News

TipRanks 1d
Oncolytics Biotech Seeks Nevada Domestication to Align with U.S. Growth Strategy

Claim 70% Off TipRanks Premium Oncolytics Biotech ( (ONCY) ) has issued an update. Oncolytics Biotech has outlined its strategic rationale for a proposed chan...

TipRanks 1d
Oncolytics outlines strategic rationale for proposal to change jurisdiction

Oncolytics (ONCY) Biotech provided additional context regarding its previously announced proposal to change the Company’s jurisdiction of incorporation from Alb...

TipRanks 3d
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials

Claim 70% Off TipRanks Premium Oncolytics Biotech ( (ONCY) ) has provided an announcement. On January 7, 2026, Oncolytics Biotech expanded its Gastrointestina...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.